INC Research Establishes Site Advocacy Group to Improve Investigator Payments
INC Research announced the formation of a new Site Advocacy Group (SAG) under the auspices of its relationship with the Society for Clinical Research Sites (SCRS).
INC Research announced the formation of a new Site Advocacy Group (SAG) under the auspices of its relationship with the Society for Clinical Research Sites (SCRS). The Investigator Payment SAG, which will kick-off later this year, was established in response to specific feedback from sites that noted financial challenges to their ongoing sustainability as a participant in the clinical research enterprise. The Investigator Payment SAG aims to understand in depth the pain points sites experience and modernize financial processes to keep clinical research sites engaged, as well as recruit new sites.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
